JP2020536953A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020536953A5 JP2020536953A5 JP2020540680A JP2020540680A JP2020536953A5 JP 2020536953 A5 JP2020536953 A5 JP 2020536953A5 JP 2020540680 A JP2020540680 A JP 2020540680A JP 2020540680 A JP2020540680 A JP 2020540680A JP 2020536953 A5 JP2020536953 A5 JP 2020536953A5
- Authority
- JP
- Japan
- Prior art keywords
- dextromethorphan
- delivery device
- transdermal delivery
- adhesive
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 claims description 96
- 229960001985 dextromethorphan Drugs 0.000 claims description 96
- 230000037317 transdermal delivery Effects 0.000 claims description 52
- 239000000853 adhesive Substances 0.000 claims description 29
- 230000001070 adhesive effect Effects 0.000 claims description 29
- 239000012790 adhesive layer Substances 0.000 claims description 21
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 20
- 239000003961 penetration enhancing agent Substances 0.000 claims description 16
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 10
- 229960001404 quinidine Drugs 0.000 claims description 10
- 239000010410 layer Substances 0.000 claims description 9
- 230000001186 cumulative effect Effects 0.000 claims description 8
- 239000012848 Dextrorphan Substances 0.000 claims description 6
- 208000012902 Nervous system disease Diseases 0.000 claims description 6
- JAQUASYNZVUNQP-PVAVHDDUSA-N dextrorphan Chemical compound C1C2=CC=C(O)C=C2[C@@]23CCN(C)[C@@H]1[C@H]2CCCC3 JAQUASYNZVUNQP-PVAVHDDUSA-N 0.000 claims description 6
- 229950006878 dextrorphan Drugs 0.000 claims description 6
- 239000013464 silicone adhesive Substances 0.000 claims description 6
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 4
- AKOAEVOSDHIVFX-UHFFFAOYSA-N Hydroxybupropion Chemical compound OCC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 AKOAEVOSDHIVFX-UHFFFAOYSA-N 0.000 claims description 4
- 230000001430 anti-depressive effect Effects 0.000 claims description 3
- 239000000935 antidepressant agent Substances 0.000 claims description 3
- 229940005513 antidepressants Drugs 0.000 claims description 3
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims description 2
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 claims description 2
- VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 claims description 2
- AXRYRYVKAWYZBR-UHFFFAOYSA-N Atazanavir Natural products C=1C=C(C=2N=CC=CC=2)C=CC=1CN(NC(=O)C(NC(=O)OC)C(C)(C)C)CC(O)C(NC(=O)C(NC(=O)OC)C(C)(C)C)CC1=CC=CC=C1 AXRYRYVKAWYZBR-UHFFFAOYSA-N 0.000 claims description 2
- 108010019625 Atazanavir Sulfate Proteins 0.000 claims description 2
- 206010011224 Cough Diseases 0.000 claims description 2
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical group C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 claims description 2
- LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 claims description 2
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims description 2
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 claims description 2
- 230000000954 anitussive effect Effects 0.000 claims description 2
- 229940124584 antitussives Drugs 0.000 claims description 2
- AXRYRYVKAWYZBR-GASGPIRDSA-N atazanavir Chemical compound C([C@H](NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)[C@@H](O)CN(CC=1C=CC(=CC=1)C=1N=CC=CC=1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C1=CC=CC=C1 AXRYRYVKAWYZBR-GASGPIRDSA-N 0.000 claims description 2
- 229960003277 atazanavir Drugs 0.000 claims description 2
- 229960001058 bupropion Drugs 0.000 claims description 2
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 claims description 2
- 229960002626 clarithromycin Drugs 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 229960003914 desipramine Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-PUGKRICDSA-N digoxin Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1[C@@H](C)O[C@@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3C[C@@H]4[C@]([C@@H]5[C@H]([C@]6(CC[C@@H]([C@@]6(C)[C@H](O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)C[C@@H]2O)C)C[C@@H]1O LTMHDMANZUZIPE-PUGKRICDSA-N 0.000 claims description 2
- 229960005156 digoxin Drugs 0.000 claims description 2
- LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims description 2
- 230000003166 hypermetabolic effect Effects 0.000 claims description 2
- 238000000338 in vitro Methods 0.000 claims description 2
- 229960001936 indinavir Drugs 0.000 claims description 2
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 2
- 229960004130 itraconazole Drugs 0.000 claims description 2
- 229960004125 ketoconazole Drugs 0.000 claims description 2
- 239000002207 metabolite Substances 0.000 claims description 2
- 229960002296 paroxetine Drugs 0.000 claims description 2
- YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 claims description 2
- 229960003634 pimozide Drugs 0.000 claims description 2
- 229940002612 prodrug Drugs 0.000 claims description 2
- 239000000651 prodrug Substances 0.000 claims description 2
- 229960002784 thioridazine Drugs 0.000 claims description 2
- 235000014113 dietary fatty acids Nutrition 0.000 claims 6
- 229930195729 fatty acid Natural products 0.000 claims 6
- 239000000194 fatty acid Substances 0.000 claims 6
- 229920001577 copolymer Polymers 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 5
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical group O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 claims 4
- 239000004820 Pressure-sensitive adhesive Substances 0.000 claims 4
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims 3
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 claims 3
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims 3
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims 3
- 239000005642 Oleic acid Substances 0.000 claims 3
- -1 fatty acid esters Chemical class 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- RZRNAYUHWVFMIP-HXUWFJFHSA-N glycerol monolinoleate Natural products CCCCCCCCC=CCCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-HXUWFJFHSA-N 0.000 claims 3
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims 3
- 229920002367 Polyisobutene Polymers 0.000 claims 2
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 claims 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 claims 2
- 229920005573 silicon-containing polymer Polymers 0.000 claims 2
- 239000002356 single layer Substances 0.000 claims 2
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 229920001756 Polyvinyl chloride acetate Polymers 0.000 claims 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims 1
- 230000010482 emotional regulation Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 3
- TVYLLZQTGLZFBW-ZBFHGGJFSA-N (R,R)-tramadol Chemical compound COC1=CC=CC([C@]2(O)[C@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-ZBFHGGJFSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 229960004380 tramadol Drugs 0.000 description 2
- TVYLLZQTGLZFBW-GOEBONIOSA-N tramadol Natural products COC1=CC=CC([C@@]2(O)[C@@H](CCCC2)CN(C)C)=C1 TVYLLZQTGLZFBW-GOEBONIOSA-N 0.000 description 2
- KWTWDQCKEHXFFR-UHFFFAOYSA-N 3-[1-(dimethylamino)-2-methylpentan-3-yl]phenol Chemical class CN(C)CC(C)C(CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-UHFFFAOYSA-N 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010029350 Neurotoxicity Diseases 0.000 description 1
- 229940127450 Opioid Agonists Drugs 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010044221 Toxic encephalopathy Diseases 0.000 description 1
- 208000030886 Traumatic Brain injury Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 229960002504 capsaicin Drugs 0.000 description 1
- 235000017663 capsaicin Nutrition 0.000 description 1
- PCHPORCSPXIHLZ-UHFFFAOYSA-N diphenhydramine hydrochloride Chemical compound [Cl-].C=1C=CC=CC=1C(OCC[NH+](C)C)C1=CC=CC=C1 PCHPORCSPXIHLZ-UHFFFAOYSA-N 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 229940127240 opiate Drugs 0.000 description 1
- 239000003379 purinergic P1 receptor agonist Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000009529 traumatic brain injury Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023136898A JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762568028P | 2017-10-04 | 2017-10-04 | |
| US62/568,028 | 2017-10-04 | ||
| US201862680182P | 2018-06-04 | 2018-06-04 | |
| US62/680,182 | 2018-06-04 | ||
| PCT/US2018/054178 WO2019070864A1 (en) | 2017-10-04 | 2018-10-03 | DEVICE FOR TRANSDERMAL DEXTROMETHORPHAN DELIVERY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136898A Division JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020536953A JP2020536953A (ja) | 2020-12-17 |
| JP2020536953A5 true JP2020536953A5 (enExample) | 2021-11-04 |
Family
ID=65994772
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540680A Pending JP2020536953A (ja) | 2017-10-04 | 2018-10-03 | デキストロメトルファン経皮送達デバイス |
| JP2023136898A Active JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023136898A Active JP7609943B2 (ja) | 2017-10-04 | 2023-08-25 | デキストロメトルファン経皮送達デバイス |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US11382869B2 (enExample) |
| EP (1) | EP3691641A4 (enExample) |
| JP (2) | JP2020536953A (enExample) |
| KR (1) | KR20200062254A (enExample) |
| CN (1) | CN111343980B (enExample) |
| AU (1) | AU2018345723B2 (enExample) |
| BR (1) | BR112020006723A2 (enExample) |
| CA (1) | CA3078369A1 (enExample) |
| IL (1) | IL273735B2 (enExample) |
| MX (1) | MX2020003044A (enExample) |
| TW (1) | TWI795446B (enExample) |
| WO (1) | WO2019070864A1 (enExample) |
| ZA (1) | ZA202001834B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
| US20240216358A1 (en) * | 2020-03-30 | 2024-07-04 | Shinkei Therapeutics Llc | Transdermal delivery of dextromethorphan |
| CN117100750A (zh) * | 2020-07-20 | 2023-11-24 | 深圳信立泰药业股份有限公司 | 一种药物组合物及其应用 |
| JP2024503114A (ja) * | 2021-01-18 | 2024-01-24 | アンテシップ バイオベンチャーズ トゥー エルエルシー | 神経精神疾患に対する抗うつ剤とデキストロメトルファンとの組み合わせ |
| CN113720944B (zh) * | 2021-09-30 | 2023-04-28 | 珠海润都制药股份有限公司 | 一种氢溴酸右美沙芬硫酸奎尼丁胶囊含量的检测方法 |
| AU2023356341A1 (en) * | 2022-10-06 | 2025-05-15 | Shinkei Therapeutics, Inc. | Transdermal delivery of dextromethorphan |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3020630B2 (ja) * | 1991-03-27 | 2000-03-15 | 三井化学株式会社 | 薬物投与用粘着剤 |
| US5206248A (en) | 1992-03-27 | 1993-04-27 | Smith Richard A | Method for reducing emotional lability |
| WO1995024172A1 (en) * | 1994-03-07 | 1995-09-14 | Theratech, Inc. | Drug-containing adhesive composite transdermal delivery device |
| SE9601528D0 (sv) * | 1996-04-23 | 1996-04-23 | Pharmacia Ab | Transdermally administered dextromethorphan as antitissue agent |
| TWI326214B (en) | 2002-07-17 | 2010-06-21 | Avanir Pharmaceuticals Inc | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders |
| WO2004017941A2 (en) * | 2002-08-20 | 2004-03-04 | Euro-Celtique, S.A. | Transdermal dosage form comprising an active agent and a salt and free-baseform of an antagonist |
| CA2548596A1 (en) * | 2003-12-10 | 2005-06-23 | Acrux Dds Pty Ltd. | Method of treatment for undesired effect following transdermal or topical drug delivery |
| US20060223786A1 (en) | 2005-04-01 | 2006-10-05 | Smith David J | Transdermal pain control method and device |
| BRPI0607017B8 (pt) * | 2005-04-06 | 2021-05-25 | Adamas Pharmaceuticals Inc | composição farmacêutica compreendendo memantina e donezepil, e seu uso para o tratamento de condições relacionadas ao snc |
| KR20080097443A (ko) * | 2006-02-03 | 2008-11-05 | 아바니르 파마슈티컬스 | 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물 |
| US20070248657A1 (en) * | 2006-04-25 | 2007-10-25 | Smith David J | Multi-compartment transdermal pain control device |
| EA200970369A1 (ru) * | 2006-10-09 | 2009-08-28 | Смитклайн Бичам Корпорейшн | Композиции для снижения симптомов никотиновой абстиненции и/или отказа от употребления табака |
| WO2009021058A2 (en) * | 2007-08-06 | 2009-02-12 | Trinity Labortories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
| WO2010062690A1 (en) * | 2008-10-30 | 2010-06-03 | Concert Pharmaceuticals Inc. | Combination of morphinan compounds and antidepressant for the treatment of pseudobulbar affect, neurological diseases, intractable and chronic pain and brain injury |
| JP5680061B2 (ja) * | 2009-04-24 | 2015-03-04 | ヘンケル・ユーエス・アイピー・リミテッド・ライアビリティ・カンパニーＨｅｎｋｅｌ ＵＳ ＩＰ ＬＬＣ | シリコーンアクリルハイブリッドポリマーを基剤とする接着剤 |
| US20140051718A1 (en) | 2012-04-16 | 2014-02-20 | Antecip Bioventures Ii Llc | Compositions and Methods Comprising Celecoxib or Related Compounds and Dextromethorphan |
| JP6605485B2 (ja) * | 2013-11-05 | 2019-11-13 | アンテシップ バイオベンチャーズ トゥー エルエルシー | ブプロピオンまたは関連組成物およびデキストロメトルファンを含む組成物 |
| TWI795446B (zh) * | 2017-10-04 | 2023-03-11 | 美商神經治療股份有限公司 | 右旋美索芬(dextromethorphan)經皮輸送裝置 |
-
2018
- 2018-10-02 TW TW107134828A patent/TWI795446B/zh active
- 2018-10-03 CA CA3078369A patent/CA3078369A1/en active Pending
- 2018-10-03 WO PCT/US2018/054178 patent/WO2019070864A1/en not_active Ceased
- 2018-10-03 EP EP18864063.5A patent/EP3691641A4/en active Pending
- 2018-10-03 CN CN201880072989.3A patent/CN111343980B/zh active Active
- 2018-10-03 IL IL273735A patent/IL273735B2/en unknown
- 2018-10-03 KR KR1020207011696A patent/KR20200062254A/ko not_active Ceased
- 2018-10-03 US US16/753,471 patent/US11382869B2/en active Active
- 2018-10-03 AU AU2018345723A patent/AU2018345723B2/en active Active
- 2018-10-03 MX MX2020003044A patent/MX2020003044A/es unknown
- 2018-10-03 BR BR112020006723-7A patent/BR112020006723A2/pt unknown
- 2018-10-03 JP JP2020540680A patent/JP2020536953A/ja active Pending
-
2020
- 2020-03-23 ZA ZA2020/01834A patent/ZA202001834B/en unknown
-
2022
- 2022-07-06 US US17/858,471 patent/US20220331264A1/en not_active Abandoned
-
2023
- 2023-08-25 JP JP2023136898A patent/JP7609943B2/ja active Active
- 2023-10-19 US US18/381,849 patent/US20240189252A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020536953A5 (enExample) | ||
| JP6845162B2 (ja) | ケタミン経皮送達システム | |
| US20220395469A1 (en) | Transdermal drug delivery system for ketamine | |
| JP5938612B2 (ja) | 経皮吸収治療システム | |
| RU2408368C2 (ru) | Препараты соли бупропиона с модифицированным высвобождением | |
| JP6301356B2 (ja) | ロチゴチンの経皮投与のための複数日用のパッチ | |
| TWI704933B (zh) | 右美托咪啶經皮輸送裝置及使用其之方法 | |
| JP6109280B2 (ja) | 活性物質の利用率及び用量精度の高い経皮治療システム | |
| RU2007122410A (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту | |
| KR102771688B1 (ko) | 바레니클린의 경피 투여를 위한 약학 제제 | |
| CN103432104B (zh) | 一种含有普拉克索的透皮贴剂 | |
| CN105764496B (zh) | 用于经皮递送非镇静量的右旋美托咪啶的方法和组合物 | |
| TW201206506A (en) | Propynylaminoindan transdermal compositions | |
| WO2011050728A1 (zh) | 一种稳定的雷沙吉兰组合物 | |
| JP7049258B2 (ja) | 水性貼付剤 | |
| JP2022530345A (ja) | 経皮治療システム | |
| US20080160068A1 (en) | Method for a Medicinal Combination Treatment, and Medicament Combinations Suitable Therefor | |
| KR102699924B1 (ko) | 프라미펙솔 경피 전달 시스템 및 그 사용 | |
| JP2011026227A (ja) | 非含水貼付製剤 | |
| TWI745577B (zh) | 經皮吸收製劑 | |
| CN117797130A (zh) | S-氯胺酮经皮组合物及其制备方法和应用 | |
| JP2021102573A (ja) | クエン酸フェンタニル含有経皮吸収製剤 | |
| US20190022024A1 (en) | Transdermal patch |